智通财经APP获悉，复宏汉霖(02696)午后涨超4%，截至发稿，涨4.33%，报22.9港元，成交额3827.59万港元。
消息面上，复宏汉霖自主开发和生产的汉贝泰(贝伐珠单抗注射液)正式获得玻利维亚国家药品与卫生技术局批准上市，标志着汉贝泰成为继汉曲优(曲妥珠单抗)、H药汉斯状(斯鲁利单抗)、汉利康(利妥昔单抗)后，复宏汉霖第四款在海外获批上市的自主研发和生产的产品。此次获批是基于复宏汉霖与巴西及拉美地区领先的制药公司Eurofarma的独家商业化合作。
此外，复宏汉霖于2月10日公布，一项注射用HLX43(靶向PD-L1抗体－新型DNA拓扑异构酶I抑制剂偶联药物)在复发或转移性食管鳞癌患者中开展的2期临床研究在内地完成首例患者给药。公司指，计划于条件具备后开展用于宫颈癌、肝细胞癌、鼻咽癌、头颈部鳞癌、非小细胞肺癌等潜在适应症治疗的相关2期临床试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.